Brainlab AG considers Frankfurt IPO, potential valuation at EUR 2 billion

Investing.com — Medical (TASE:) technology firm Brainlab AG is reportedly exploring options for an initial public offering (IPO) in Frankfurt, according to Bloomberg sources familiar with the situation. The Munich-based company, known for its advancements in medical technology, has sought bank proposals for the potential share sale, the sources revealed.

The IPO could potentially take place in the second half of 2025, valuing the company at around €2 billion ($2.1 billion). However, these plans are still in the discussion stage, with the potential size and timeline of the IPO subject to change.

In response to a query from Bloomberg News, Brainlab stated, “Brainlab is keeping all options open in order to promote long-term growth and maximize shareholder value.” The company clarified that no decision on an IPO has been made yet and no mandate has been given to banks.

Brainlab, which has been working with an adviser to seek bank pitches for the share sale, has not disclosed any further details about the potential IPO. The sources, who requested anonymity due to the private nature of the information, stressed that the company’s deliberations are ongoing.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.